Introduction: Favorable outcomes are observed after treatment with standard chemoradiotherapy (CRT) for Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) patients. The consistent growing interest on treatment-related toxicity burden, potentially jeopardizing survivors’ quality of life, led clinicians to investigate possible de-escalation strategies. Materials and Methods: A comprehensive systematic literature search of clinical trials was performed through the EMBASE database to provide an overview of the de-escalation strategies spectrum. Additionally, hand searching and clinicaltrials.gov were also used. Results: Herein, we report and discuss different approaches to de-escalation of therapy, with respect to both local and systemic strategies. Conclusions: Several promising de-escalation experiences have been published. However, while further evidence is awaited, no changes in the management nor deviation from the standard of care should be made outside of clinical trials.

Decreasing treatment burden in HPV-related OPSCC: A systematic review of clinical trials

Iorio G. C.;Arcadipane F.;Ricardi U.;
2021

Abstract

Introduction: Favorable outcomes are observed after treatment with standard chemoradiotherapy (CRT) for Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) patients. The consistent growing interest on treatment-related toxicity burden, potentially jeopardizing survivors’ quality of life, led clinicians to investigate possible de-escalation strategies. Materials and Methods: A comprehensive systematic literature search of clinical trials was performed through the EMBASE database to provide an overview of the de-escalation strategies spectrum. Additionally, hand searching and clinicaltrials.gov were also used. Results: Herein, we report and discuss different approaches to de-escalation of therapy, with respect to both local and systemic strategies. Conclusions: Several promising de-escalation experiences have been published. However, while further evidence is awaited, no changes in the management nor deviation from the standard of care should be made outside of clinical trials.
160
103243
103252
Cetuximab; Cisplatin; De-escalation; De-intensification; HPV; Oropharynx cancer; Radiotherapy; TORS; Chemoradiotherapy; Clinical Trials as Topic; Humans; Quality of Life; Carcinoma, Squamous Cell; Oropharyngeal Neoplasms; Papillomavirus Infections
Iorio G.C.; Arcadipane F.; Martini S.; Ricardi U.; Franco P.
File in questo prodotto:
File Dimensione Formato  
Decreasing treatment burden...2021.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 1.54 MB
Formato Adobe PDF
1.54 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1795784
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact